Dana-Farber’s revolutionary discoveries are changing cancer treatment everywhere.

Dana-Farber has played a foundational role in more than half the cancer drugs approved by the FDA since 2018.

What we do here
changes lives everywhere

When you follow the science, one thing leads to another. A new insight takes a previous breakthrough further. Thanks to our momentum of discovery, living with cancer is less of a burden, and living without cancer is a greater possibility.

One cancer discovery after another for over 75 years.

FDA approves kidney cancer therapy after Dana-Farber-led research shows improved outcomes for patients with advanced disease
Belzutifan, a HIF-2α inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced kidney cancer previously treated with immune checkpoint inhibitors and anti-angiogenic therapies.
Dana-Farber research supports FDA approval of new therapy for metastatic breast cancer
Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic HR+, HER2- breast cancer. The FDA action was based on the results of T...
Dana-Farber Led Study Leads to FDA Approval for Next-Generation Drug in Relapsed Chronic Lymphocytic Leukemia
On Thursday, January 19, 2023, the FDA approved zanubrutinib, a next-generation BTK inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The approval was based, in part, on findings from...